Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
24
11
2022
Statut:
ppublish
Résumé
TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. The results of a cohort of patients with colorectal cancer (CRC) with Eligible patients had advanced CRC, no standard treatment options, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with Thirty patients were enrolled from August 2016 to August 2018; all had CRC with a The combination of C + V has antitumor activity in heavily pretreated patients with CRC with
Substances chimiques
Vemurafenib
207SMY3FQT
cobimetinib
ER29L26N1X
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Sulfonamides
0
Indoles
0
Antineoplastic Agents
0
BRAF protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM